Iconovo (ICO.ST) Stock Analysis & AI Equity Report
Iconovo (ICO.ST) overview
Iconovo (ICO.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Iconovo reported revenue of SEK 2.9m and operating profit of SEK -41.1m; the year-end share price was 4.14 SEK and market capitalisation was SEK 66.3m. Iconovo is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Iconovo's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Iconovo
Iconovo AB develops inhaled medicines and dry powder inhaler platforms for pharmaceutical partners. Its business combines patented device technologies with formulation development, supporting projects from early development through preclinical studies and later partnering. The company also has a Nordic sales focus through Iconovo Pharma for selected generic and proprietary inhalation products.
Generate the Iconovo report
Iconovo is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Iconovo and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.